Help us validate biomarkers that may help ALS therapy development
Closed for enrollment
Study Name
CReATe Consortium: TRIAL READY Study
PI
Michael Benatar, MD, PhD
Study Type
Observational, Longitudinal and cross-sectional
Eligible Population
- Individuals affected with ALS or a related neurodegenerative disorder, including ALS-FTD, FTD, PLS, and PMA.
- Healthy controls
Study Purpose/Goals
To validate the following as biomarkers of ALS and related disorders:
(a) NfL and pNfH in blood and cerebrospinal fluid
(b) Urinary p75ECD
Procedures/Participation
Up to 5 half-day study visits in Miami over a 1-year period
- Family and medical history review
- Genetic counseling
- Genetic Testing (with choice to learn results or remain blinded)
- Collect blood, urine, and CSF fluid (CSF optional)
- Neurological exam
- Neuropsychological exam
- Breathing testing
- Surveys
(Specific procedures depend on whether participating as a control or as an individual affected with ALS or related disorder)
Links
Contact
Join our family - together, we can change the course of this disease.
Join our family
Together, we can change the course of this disease.
ALS Treatment
About Us
Copyright © 2020. ALS Center at the University of Miami. All Rights Reserved. Branding by Mok2